Jaguar Health Licenses FDA-Approved Oral Mucositis Product For U.S. Market, Initiating Commercial Footprint In Its Core Focus Area Of Cancer Supportive Care; Planning To Begin Commercial Launch In Q3 2024 For Gelclair
Benzinga Newsdesk - Apr 16, 2024, 8:35AM